Medivir receives €2.6 million for hepatitis C collaboration
This article was originally published in Scrip
Executive Summary
Medivir has received a €2.6 million milestone payment from Tibotec after the Belgian Johnson & Johnson subsidiary selected a hepatitis C preclinical development candidate. The Swedish firm has a research, development and licence agreement with Ortho Biotech Products and Tibotec to identify and develop orally active inhibitors of the hepatitis C virus polymerase NS5B (Scrip Online, May 21st, 2008). Tibotec is responsible for the development of the candidate through to marketing and has exclusive worldwide marketing rights except in the Nordic countries, which Medivir has retained. The two firms are developing TMC435 (formerly TMC435350), currently in Phase IIa studies, which inhibits the NS3 protease enzyme.
You may also be interested in...
Innovation not M&A to drive Bayer growth in LatAm
Laura Gonz�lez-Molero will be celebrating her first anniversary as President of Bayer HealthCare Pharmaceuticals, Latin America this month. With Bayer posting total sales of €1.05bnin Latin America in 2014, up 13% over 2013, Ms Gonz�lez-Molero should be pleased with a successful inaugural year. Resolute in her belief that innovation, "part of Bayer's DNA," will determine the company's long-term success in Latin America, rather than growth through acquisition, Ms Gonz�lez-Molero talks to Scrip about her personal ambitions for the company and the region.
2010 Scrip 100 - Is Anvisa a friend of innovators?
A decade since its formation Anvisa, Brazil's medicines regulator, has shaken up the country's framework for ensuring drug quality. Yet the agency's approaches to drug pricing and registration have left some multinationals wanting, reports Sita Shah.
Elan raises $1.5 billion
Elan is raising $1.5 billion in bonds to refinance its existing debt and for general corporate purposes, it says.